Since the combined administration of the anti-osteopontin antibody in early and late acute phases more efficiently reduced brain edema volume and additionally reduced stroke tissue damage (Fig. 2e,f, Supplementary Fig. S10), we next sought to evaluate the therapeutic effect of the combined anti-osteopontin antibody treatment on BBB function in ischemic stroke lesions. This evidence concerns the gene SPP1 and Stroke.